You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • SAT0485 Safety Profile of the IL-1 Receptor Antagonist Kineret® (Anakinra) in a Long-Term Outcome Study in Patients with Severe Cryopyrin-Associated Periodic Syndromes (Caps)

Article info

Article menu
Download PDFPDF
Scientific Abstracts
Paediatric rheumatology
SAT0485 Safety Profile of the IL-1 Receptor Antagonist Kineret® (Anakinra) in a Long-Term Outcome Study in Patients with Severe Cryopyrin-Associated Periodic Syndromes (Caps)

Authors

Citation

Kullenberg T, Löfqvist M, Olivecrona H, et al
SAT0485 Safety Profile of the IL-1 Receptor Antagonist Kineret® (Anakinra) in a Long-Term Outcome Study in Patients with Severe Cryopyrin-Associated Periodic Syndromes (Caps)
Annals of the Rheumatic Diseases 2013;72:A745-A746.

Publication history

  • First published January 23, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions